Patient Navigator Intervention for Vision Impairment or Blindness (NYCES Trial)

N/A

Waitlist Available

Led By Lisa A. Hark

Research Sponsored by Columbia University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Individuals age 21 and older

Be older than 18 years old

Must not have

Inability to provide informed consent due to dementia or other reasons

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1-year

Summary

This trial aims to improve eye health for adults in New York City by addressing disparities in eye care access & outcomes. #EyeHealth #EyeEquity

Who is the study for?

The NYC Eye Study is for adults aged 21+ living independently in certain affordable housing areas. It's aimed at those with eye conditions like blindness, cataract, diabetic retinopathy, and glaucoma. People with terminal illnesses or unable to consent due to dementia cannot participate.

What is being tested?

This study tests whether using patient navigators can improve eye health compared to usual care without them. Patient navigators are people who help guide patients through the healthcare system to ensure they receive appropriate care.

What are the potential side effects?

Since this trial involves non-medical interventions (patient navigators), there aren't typical medication side effects. However, participants may experience stress or anxiety from additional appointments or changes in their routine.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 21 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am unable to understand and give consent for treatment due to dementia.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1-year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1-year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Adherence to Follow-up Eye Care

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Arm 1: Intervention Using Patient NavigatorsActive Control1 Intervention

Consented participants referred to ophthalmology from the 9 developments randomized to the Intervention Arm will receive ongoing support from patient navigators to assist with all aspects of follow-up eye care at either Columbia Harkness Eye Institute or Harlem Hospital Ophthalmology, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.

Group II: Arm 2: Usual Care + Automated Appointment RemindersPlacebo Group1 Intervention

Consented participants referred from the 5 developments randomized to the Usual Care Arm +Automated Appointment Reminders who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Columbia Harkness Eye Institute or Harlem Hospital Ophthalmology. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence. Arm 2 represents a realistic choice available for participants following screening over a 1-year period.

0 / 2Eligibility criteria met